- Poster presentation
- Open Access
P85 - Asthmatic children and adolescents treated in daily medical practice – results from a 2-year sublingual allergen immunotherapy (AIT) study with grass pollen tablets
© Karagiannis et al; licensee BioMed Central Ltd. 2014
Published: 28 February 2014
The aim of this non-interventional study was to document the impact of a sublingual allergen immunotherapy (AIT) with Oralair 5-grass pollen tablets (Stallergenes, France) on symptom severity (rhinitis, conjunctivitis, asthma), use of symptomatic medication and tolerability in patients with grass pollen-induced allergic rhinoconjunctivitis (RC) over 2 years of routine medical practice treatment. This poster focuses on the subgroup of asthmatic children (4-11 yrs) and adolescents (12-17 yrs).
This prospective, open, non-controlled, non-interventional, multicenter study was conducted from September 2010 to October 2012 in Germany. Overall 1.482 patients (93 asthmatic children (6.2%), 73 asthmatic adolescents (4.9%)) participated in the study.
The patients rated their symptoms as a combined score of severity (scale: 0 [none] – 3 [severe]) and frequency (scale: 0 [none] – 4 [very often]). In the combined RC score, the severity of rhinitis and conjunctivitis were pooled (scale: 0 [none] – 6 [severe]). In the asthma score, the severity and the frequency were pooled (scale: 0 [none] – 7 [severe]).
During the season preceding AIT treatment 93/ 92% of children/ adolescents with asthma had used symptomatic medication for RC symptoms. This rate dropped to 64/ 68% (1st season) and to 57/ 41% (2nd season). Likewise the RC score in these patients decreased from 4.06/ 4.13 to 1.86/ 1.82 (1st year) and to 1.33/ 1.59 (2nd year). Also the asthma score was reduced from 3.36/ 3.55 to 1.24/ 1.51 (1st year) to 0.71/ 1.13 (2nd year).
An improvement in health status after two years of treatment was documented by 96/ 96%.
Adverse events occurred in 19.4/ 17.8% over two years of treatment. The incidence of non-fatal serious adverse events was 3.2/ 0.0%.
At the end of the 2nd season, 96/ 96% evaluated the tolerability of the 5-grass pollen tablets as very good or good.
Based on the study results, AIT with Oralair 5-grass pollen tablets was well tolerated by children and adolescents with asthma in routine medical practice. Symptomatic medication for RC symptoms use was significantly reduced. The asthma- and the RC score were also reduced significantly after one and two years under treatment with Oralair 5-grass pollen tablets compared to the season preceding AIT.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.